Primary myelofibrosis Trials in London, United Kingdom
Conditions / Primary myelofibrosis / London, United Kingdom
Research into Primary myelofibrosis spans multiple therapeutic approaches and trial phases.
19 total trials for this combination
Showing top 10 of 19 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04173494 | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | COMPLETED | PHASE3 |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | COMPLETED | PHASE1/PHASE2 |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | TERMINATED | PHASE3 |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | TERMINATED | PHASE3 |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT04603495 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | TERMINATED | PHASE3 |
| NCT06479135 | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | RECRUITING | PHASE3 |